Companies › Shanghai Escugen Biotechnology
2 active drug programs in 2 registered trials: 2 Phase 1; Hematology, Oncology; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ESG206 | – | Phase 1 | Immune Thrombocytopenia (ITP) | Apr 2027 |
| ESG406 | – | Phase 1 | Locally Advanced/Metastatic Solid Tumors | Apr 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06853444 | ESG206 | Phase 1 | Immune Thrombocytopenia (ITP) | Hematology | Apr 2027 |
| NCT06979674 | ESG406 | Phase 1 | Locally Advanced/Metastatic Solid Tumors | Oncology | Apr 2028 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.